BiotechTube
Alzprotect

Alzprotect

Lille, France· Est.
alzprotect.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

Alzprotect is a clinical-stage biotech developing AZP2006, a small molecule with a unique, multi-target mechanism for treating neurodegenerative tauopathies. The company's lead program is currently in a Phase 2a platform trial for Progressive Supranuclear Palsy (PSP) and holds Orphan Drug Designation in both the US and EU. With a strategy to advance its candidate through early clinical proof-of-concept and then seek partnerships with larger pharmaceutical companies, Alzprotect is targeting major unmet needs in Alzheimer's, PSP, and potentially Parkinson's disease.

Neurodegenerative DiseasesTauopathies

Technology Platform

Small molecule (AZP2006) with a novel multi-target mechanism of action designed to simultaneously address amyloid-beta, tau protein, neuroinflammation, and oxidative stress.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The primary opportunity is addressing the massive, unmet need in Alzheimer's disease with a potentially superior, multi-target therapy.
Success in the ongoing PSP trial, facilitated by orphan designation and a platform study design, offers a faster path to proof-of-concept and significant value creation, enabling expansion into larger markets.

Risk Factors

The lead candidate faces high clinical development risk in a field with a history of frequent failures.
As a pre-revenue company, it carries significant financing risk and depends on successful capital raises.
It also operates in the highly competitive and scientifically challenging Alzheimer's disease landscape.

Competitive Landscape

Alzprotect competes in the crowded neurodegeneration space, notably against large pharma and biotechs focused on amyloid (e.g., Eisai/Biogen) and tau (e.g., AC Immune, Biogen). Its key differentiator is its claimed multi-target mechanism. In PSP, it competes directly with other tau-targeting therapies like Axon Neuroscience's AADvac1, which is in the same platform trial.

More companies in Small Molecule Drugs →More companies in France →